This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GAP-486, ZP123, ZP-123
Rotigaptide is a novel compound developed with the aim of preventing life threatening ventricular arrhythmia by re-establishing heart tissue conductance and function by modifying gap-junction communication.
Gap-junctions are specialized pores that ensure the coordinated transmission of electrical impulses from cell-to-cell, which is essential for synchronized contraction. This spreading of electrical impulses is scrambled following heart attack (myocardial infarction), which may lead to irregular heart beats, or arrhythmia, followed by cardiac arrest and death.
ZP123 was originally developed by Zealand Pharma.
In May 2003, Zealand entered into a development and license agreement with Wyeth. Under the terms of the agreement, the two companies will co-develop ZP123.
The two companies will collaborate to conduct pre-clinical studies, while Wyeth would conduct future clinical development. Under the terms of the agreement, Zealand will receive research funding and milestone payments as well as royalties on potential future sales, assuming successful development and approval of a final product.
As part of the agreement, Zealand has granted Wyeth an exclusive option for a broad collaboration programme to identify additional novel drug candidates based on gap junction modulation as a mechanism of action.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total...See full deal structure in Biomedtracker
Partners: Zealand Pharma A/S
Additional information available to subscribers only: